117 related articles for article (PubMed ID: 38686902)
1. Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level.
Kao YW; Chao TF; Chen SW; Cheng YW; Chan YH; Chu PH
J Am Heart Assoc; 2024 May; 13(9):e033236. PubMed ID: 38686902
[TBL] [Abstract][Full Text] [Related]
2. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
[TBL] [Abstract][Full Text] [Related]
3. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Abnormal Serum Potassium Level.
Hwang YJ; Lyu B; Chang AR; Inker LA; Grams ME; Shin JI
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1094-1096. PubMed ID: 34491898
[No Abstract] [Full Text] [Related]
5. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
[TBL] [Abstract][Full Text] [Related]
6. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
[TBL] [Abstract][Full Text] [Related]
8. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
[TBL] [Abstract][Full Text] [Related]
10. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
[TBL] [Abstract][Full Text] [Related]
11. Is GFR decline induced by SGLT2 inhibitor of clinical importance?
Günes-Altan M; Bosch A; Striepe K; Bramlage P; Schiffer M; Schmieder RE; Kannenkeril D
Cardiovasc Diabetol; 2024 May; 23(1):184. PubMed ID: 38811998
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study.
Lin FJ; Wang CC; Hsu CN; Yang CY; Wang CY; Ou HT
Cardiovasc Diabetol; 2021 Oct; 20(1):203. PubMed ID: 34620182
[TBL] [Abstract][Full Text] [Related]
13. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
[TBL] [Abstract][Full Text] [Related]
16. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
Hirai T; Kitada M; Monno I; Oda E; Hayashi Y; Shimada K; Takagaki Y; Ogura Y; Fujii M; Konishi K; Sakurai M; Nakagawa A; Koya D
J Diabetes Investig; 2021 Sep; 12(9):1577-1585. PubMed ID: 33417741
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database.
Kanaoka T; Wakui H; Yano Y; Nagasu H; Kanegae H; Nangaku M; Hirakawa Y; Nakagawa N; Wada J; Tsuruya K; Nakano T; Maruyama S; Wada T; Konishi M; Nagahiro T; Yamagata K; Narita I; Yanagita M; Terada Y; Araki S; Emoto M; Okada H; Isaka Y; Suzuki Y; Yokoo T; Kataoka H; Kanda E; Kashihara N; Tamura K;
Diabetes Obes Metab; 2024 Jul; 26(7):2905-2914. PubMed ID: 38719436
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
Xie Y; Bowe B; Gibson AK; McGill JB; Yan Y; Maddukuri G; Al-Aly Z
Diabetes Care; 2020 Nov; 43(11):2785-2795. PubMed ID: 32912850
[TBL] [Abstract][Full Text] [Related]
20. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]